The Helloworld Travel Ltd (ASX: HLO) share price has come under pressure on the day of its annual general meeting.
In early afternoon trade, the travel booking company's shares are down over 3.5% to $2.95.
Image source: Getty Images
Why is the Helloworld share price dropping lower?
Today's decline appears to have less to do with its annual general meeting and more to do with a piece of COVID-19 vaccine news.
Fellow travel bookers Flight Centre Travel Group Ltd (ASX: FLT) and Webjet Limited (ASX: WEB) have also come under pressure today after concerns were raised with the data from the AstraZeneca COVID-19 vaccine candidate.
Last week, that data showed that when trial participants were given a half dose, followed by a full dose at least one month apart, the vaccine was 90% effective. Whereas, when given as two full doses at least one month apart, the vaccine showed just 62% efficacy.
Overnight, the UK-based pharmaceutical giant revealed that the more effective dosage was actually administered by accident and due to a manufacturing error.
It also came to light that the more effective dosage was given only to a lower risk group, which sparked fears that it may not be as effective against higher risk individuals.
In light of this, AstraZeneca looks set to have to undertake another clinical trial to prove its efficacy, which could push back its launch date.
What about the Helloworld AGM?
Given that Helloworld only recently released its first quarter update, there wasn't much new information released with its presentation.
Management continues to expect FY 2021 to be a tough year and looks forward to a big improvement in the following financial years.
It commented: "The remainder of this financial year will continue to be challenging and we will continue to incur underlying EBITDA losses in the vicinity of $1.5-$2 million per month at least until the fourth quarter of FY21 however depending upon what other international bubbles may have opened up by then we're hopeful that we would be close to a break even position by the last quarter of the current financial year."
"Beyond that and looking forward into FY22, given the recent extraordinary success of the vaccine trials it is not unreasonable to assume the rest of the world will start to open up throughout the second half of 2021 and into the first half of 2022 and while we do not believe things will return to their previous levels in FY22 they will certainly continue to get better and better and we're hopeful that FY23 will see a return to our previous TTV and revenue levels," it added.
